

Patent Cap in Drug Pricing Bill Seen as Having Muted Effect

MEDIA MENTIONS | LESS THAN 1 MIN READ

July 25, 2024


By: Ryan Davis

Law360

Axinn partner [Ted Mathias](#) was quoted in the *Law360* article, “Patent Cap in Drug Pricing Bill Seen as Having Muted Effect.”

Click [here](#) to access the publication, a subscription is required.

Related People



Ted Mathias

Related Services

To subscribe to our publications, [click here](#).

Featured Insights

- GCR Live: Law Leaders Europe 2025
SPEAKING ENGAGEMENT ANTITRUST
- AHLA Annual Meeting 2025
SPEAKING ENGAGEMENT ANTITRUST
- SABA North America Annual Conference 2025
SPEAKING ENGAGEMENT ANTITRUST
- Navigating Compliance: How the 2025 Hart-Scott-Rodino Updates Are Impacting Businesses
WEBINAR ANTITRUST
- NJSBA Annual Meeting and Convention 2025
SPEAKING ENGAGEMENT INTELLECTUAL PROPERTY
- Hartford HealthCare Black and Red Gala 2025
SPONSORSHIP ANTITRUST
- Informa CompLaw Antitrust West Coast Conference 2025
SPEAKING ENGAGEMENT ANTITRUST
- AHLA Health Care Transactions Program 2025
SPONSORSHIP ANTITRUST
- IAM Live: Auto IP USA 2025
SPEAKING ENGAGEMENT INTELLECTUAL PROPERTY
- ACI 21st Annual Paragraph IV Conference
SPEAKING ENGAGEMENT INTELLECTUAL PROPERTY

© 2025 Axinn, Veltrop & Harkrider LLP. All Rights Reserved